Sugi Predict

Sugi Predict / Compounds / Deferitrin

Deferitrin

Deferitrin

SCHEMBL663744

CC1(C(=O)O)CSC(c2ccc(O)cc2O)=N1

nearest known ligand 0.36

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TYR P14679 5/20 0.35
▸ ALDH1A1 P00352 3/20 0.34
▸ ALOX5 P09917 1/20 0.34
▸ CA12 O43570 1/20 0.34
▸ CA1 P00915 1/20 0.34
▸ CA2 P00918 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ CA7 P43166 1/20 0.34
▸ CA9 Q16790 1/20 0.34
▸ CA14 Q9ULX7 1/20 0.34
▸ HSD17B1 P14061 1/20 0.34
▸ MAOB P27338 1/20 0.34
▸ AMY1A P0DUB6 1/20 0.33
▸ KDM4E B2RXH2 2/20 0.33
▸ MAPT P10636 2/20 0.33
▸ GAA P10253 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ RUNX1 Q01196 1/20 0.33
▸ CBFB Q13951 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Deferitrin SCHEMBL18103545 1.00 TYR (0.35) TYRALDH1A1ALOX5CA12CA1
Deferitrin SCHEMBL1272026 1.00 TYR (0.35) TYRALDH1A1ALOX5CA12CA1
SCHEMBL5525608 0.90 MAPT (0.36) ALDH1A1ALOX5CA12CA1CA2
SCHEMBL3305314 0.90 MAPT (0.36) ALDH1A1ALOX5CA12CA1CA2
SCHEMBL14028919 0.89 TYR (0.37) TYRALDH1A1HSD17B1MAOBKDM4E
SCHEMBL14028916 0.89 TYR (0.37) TYRALDH1A1HSD17B1MAOBKDM4E
SCHEMBL11963155 0.87 MEN1 (0.35) MAPTHPGD
SCHEMBL3301476 0.87 NPC1 (0.40) TYRALDH1A1TSHRKDM4EMAPT
SCHEMBL3301483 0.87 NPC1 (0.40) TYRALDH1A1TSHRKDM4EMAPT
SCHEMBL6314483 0.86 KDM4E (0.40) ALDH1A1CA12CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160102063-A1 METHOD OF INCREASING METABOLISM GARVAN INST MED RES (AU) 2016-04-14 — — US claimed
CN-102301235-B Stabilized antibody compositions and methods for stabilizing same ABBVIE INC 2014-11-19 — — CN claimed
US-20140336230-A1 METHOD OF INCREASING METABOLISM GARVAN INSTITUTE OF MEDICAL RESEARCH (AU) 2014-11-13 — — US claimed
CN-102301235-A Stabilized antibody compositions and methods for stabilizing same — 2011-12-28 — — CN claimed
EP-2350649-A1 STABLE ANTIBODY COMPOSITIONS AND METHODS FOR STABILIZING SAME Abbott Laboratories (US) 2011-08-03 — — EP claimed
US-20110003013-A1 METHOD OF INCREASING METABOLISM GARVAN INSTITUTE OF MEDICAL RESEARCH 2011-01-06 — — US claimed
US-20100172862-A1 STABLE ANTIBODY COMPOSITIONS AND METHODS OF STABILIZING SAME ABBOTT LABORATORIES (US) 2010-07-08 — — US claimed
WO-2010062896-A1 STABLE ANTIBODY COMPOSITIONS AND METHODS FOR STABILIZING SAME ABBOTT LABORATORIES (US) 2010-06-03 — — WO claimed
EP-2191829-A2 Treatment of endocrine dysfunction using iron chelators Novartis AG (CH) 2010-06-02 — — EP claimed
US-20100004303-A1 TREATMENT OF ENDOCRINE DYSFUNCTION USING IRON CHELATORS NOVARTIS AG (CH) 2010-01-07 — — US claimed
WO-2009086592-A1 METHOD OF INCREASING METABOLISM GARVAN INSTITUTE OF MEDICAL RESEARCH (AU) 2009-07-16 — — WO claimed
EP-2049108-A1 TREATMENT OF ENDOCRINE DYSFUNCTION USING IRON CHELATORS Novartis AG (CH) 2009-04-22 — — EP claimed
EP-1667727-B1 POLYAMINE-METAL CHELATOR CONJUGATES UNIV FLORIDA (US) 2008-07-09 — — EP claimed
WO-2008015021-A1 TREATMENT OF ENDOCRINE DYSFUNCTION USING IRON CHELATORS NOVARTIS AG (CH) 2008-02-07 — — WO claimed
EP-1667727-A2 POLYAMINE-METAL CHELATOR CONJUGATES University of Florida Research Foundation, Inc. (US) 2006-06-14 — — EP claimed
WO-2005023310-A2 POLYAMINE-METAL CHELATOR CONJUGATES UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2005-03-17 — — WO claimed
EP-4725559-A2 DOSING REGIMENS FOR TREATING METAL-MEDIATED CONDITIONS Abfero Pharmaceuticals, Inc. (US) 2026-04-15 — — EP disclosed
US-11504394-B2 Targeted ionophore-based metal delivery THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-11-22 — — US disclosed
US-20030220504-A1 Synthesis of benzonitriles from substituted benzaldehyde GENZYME CORPORATION 2003-11-27 — — US disclosed
US-20030088105-A1 Process for the preparation of substituted thiazolines and their intermediates DSM FINE CHEMICALS AUSTRIA NFG GMBH & COKG (AT) 2003-05-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003013-A1 METHOD OF INCREASING METABOLISM HIF1A, HIF1AN, PC TYR 2701/4885ALDH1A1 409/4885ALOX5 822/4885
US-20030220504-A1 Synthesis of benzonitriles from substituted benzaldehyde FTH1, FGB, DBF4 TYR 246/4885ALDH1A1 1525/4885ALOX5 403/4885
US-11504394-B2 Targeted ionophore-based metal delivery SLC8B1, SLC47A2, ATP2A2 TYR 4397/4885ALDH1A1 3786/4885ALOX5 4241/4885
US-20030088105-A1 Process for the preparation of substituted thiazolines and their intermediates CBR1, RCOR1, MT-CO1 TYR 1676/4885ALDH1A1 106/4885ALOX5 2333/4885
US-20140336230-A1 METHOD OF INCREASING METABOLISM HIF1A, HIF1AN, PC TYR 2701/4885ALDH1A1 406/4885ALOX5 842/4885
US-20100004303-A1 TREATMENT OF ENDOCRINE DYSFUNCTION USING IRON CHELATORS SLC40A1, FECH, SHBG TYR 2316/4885ALDH1A1 2179/4885ALOX5 1607/4885
US-20160102063-A1 METHOD OF INCREASING METABOLISM HIF1A, HIF1AN, PC TYR 2701/4885ALDH1A1 409/4885ALOX5 822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.